Shortly after her first work anniversary, an oncolytic player abruptly terminates its CMO and eliminates the job

A little more than a year after Replimune CEO Philip Astley-Sparke recruited Andrea Pirzkall from BeiGene to run the development programs for its oncolytic immuno-gene therapy cancer treatments, he’s now abruptly showing her out.

The experienced drug developer was terminated “without cause,” the biotech disclosed in an SEC filing. The...

Click to view original post